In view of the growing prevalence of AD worldwide, there is an urgent  need for the development of better diagnostic tools and more effective  therapeutic interventions. Indeed, much work in this field has been done  during last decades. As such, a major goal of current clinical research in AD  is to improve early detection of disease and presymptomatic detection of  neuronal dysfunction, concurrently with the development of better tools  to assess disease progression in this group of disorders. All these putative  correlates are commonly referred to as AD-related biomarkers. The ideal  biomarker  should  be  easy  to  quantify  and  measure,  reproducible,  not  subject to wide variation in the general population and unaffected by co- morbid factors. For evaluation of therapies, a biomarker needs to change  linearly  with  disease  progression  and  closely  correlate  with  established  clinico-pathological parameters of the disease. 

There is growing evidence that the use of biomarkers will increase our  ability to better indentify the underlying biology of AD, especially in its early  stages. These biomarkers will improve the detection of the patients suitable  for research studies and drug trials, and they will contribute to a better  management of the disease in the clinical practice. Indeed, much work in  this field has been done during last decades. The vast number of important  applications, combined with the untamed diversity of already identified  biomarkers, show that there is a pressing need to structure the research  made on AD biomarkers into a solid, comprehensive and easy to use tool to  de deployed in clinical settings.

To date there are few publications compiling results on this topic. That is why  when I was asked to address this task I accepted inmediately. I am happy  to present you a bundle of the best articles published about biomarkers for  Alzheimer’s disease in recent times.